Business Description

Principia Biopharma Inc
NAICS : 325412 SIC : 2834
https://www.principiabio.com
220 East Grand Avenue, South San Francisco, CA, USA, 94080
Compare
Compare
TGTXTPTXINORARXALECADCTICPTKRTXAPLSALKSOCSE:NOVO BASX:CSLVRTXREGNXKRX:207940SGENMRNAALXNXKRX:068270INCY
Traded in other countries / regions
IPO Date
2018-09-14
Description
Principia Biopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapies for immunology and oncology. Its proprietary Tailored Covalency platform enables to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities. The company pipeline products include PRN1008 and PRN2246 and PRN1371 under BTK franchise.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 21.54
Equity-to-Asset 0.91
Debt-to-Equity 0.04
Debt-to-EBITDA -0.21
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 55.63
Distress
Grey
Safe
Beneish M-Score -3.31
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 0.1
3-Year EPS without NRI Growth Rate 11
3-Year FCF Growth Rate 3

Momentum Rank

Name Current Vs Industry Vs History
6-1 Month Momentum % 84.7
12-1 Month Momentum % 229.86

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 17.01
Quick Ratio 17.01

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -33.7

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -151.42
Net Margin % -140.74
FCF Margin % -190.14
ROE % -25.51
ROA % -23.25
ROIC % -163.56
ROC (Joel Greenblatt) % -564.9
ROCE % -24.72
Years of Profitability over Past 10-Year 1

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 67.22
PB Ratio 8.98
Price-to-Tangible-Book 9.44
EV-to-EBIT -41.12
EV-to-EBITDA -42.34
EV-to-Revenue 58.12
Price-to-Net-Current-Asset-Value 9.91
Price-to-Net-Cash 11.77
Earnings Yield (Greenblatt) % -2.43
FCF Yield % -3

Financials

PRNB's 30-Y Financials
AAPL
Income Statement Breakdown FY
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:PRNB

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Principia Biopharma Inc Executives

Details

GF Value

PRNB

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 50
EPS (TTM) ($) -2.41
Beta 0
Volatility % 70.79
14-Day RSI 0
14-Day ATR ($) 0
20-Day SMA ($) 0
12-1 Month Momentum % 229.86
52-Week Range ($) 25.35 - 101.89
Shares Outstanding (Mil) 33.24

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Principia Biopharma Inc Filings

Filing Date Document Date Form
No Filing Data

Principia Biopharma Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Principia Biopharma Inc Frequently Asked Questions

What is Principia Biopharma Inc(PRNB)'s stock price today?
The current price of PRNB is $100.05. The 52 week high of PRNB is $101.89 and 52 week low is $25.35.
When is next earnings date of Principia Biopharma Inc(PRNB)?
The next earnings date of Principia Biopharma Inc(PRNB) is .
Does Principia Biopharma Inc(PRNB) pay dividends? If so, how much?
Principia Biopharma Inc(PRNB) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.